TG Therapeutics CEO to speak at Cantor Global Healthcare Conference

NEW YORK, Sept. 03, 2026 /CourierPR/ -- TG Therapeutics, Inc. (NASDAQ: TGTX) will participate in the Cantor Global Healthcare Conference, where the company’s Chairman and CEO, Michael S. Weiss, will deliver a fireside chat on September 9, 2026, at 11:30 a.m. ET.

The event, which runs from September 9 to 11, 2026, will provide a platform for Weiss to discuss the company’s latest developments and future strategies. Attendees can tune in live via a webcast available on TG Therapeutics’ website at the Events section within the Investors & Media area. The full URL for the webcast is http://ir.tgtherapeutics.com/events.

TG Therapeutics is a fully integrated biotechnology company specializing in the development and commercialization of novel treatments for B-cell diseases. The company has already seen success with BRIUMVI® (ublituximab-xiiy), which was approved by the U.S. Food and Drug Administration (FDA) for treating adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BRIUMVI has also received approval from regulatory bodies outside the U.S. for treating adult patients with RMS who have active disease defined by clinical or imaging features.

"We are excited to participate in the Cantor Global Healthcare Conference," said Michael S. Weiss, Chairman and CEO of TG Therapeutics. "This provides an excellent opportunity to share our insights and advancements with healthcare professionals and investors alike."